

# Si-Cong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7580237/publications.pdf>

Version: 2024-02-01

8  
papers

169  
citations

2682572

2  
h-index

1872680

6  
g-index

8  
all docs

8  
docs citations

8  
times ranked

181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. <i>Theranostics</i> , 2020, 10, 11080-11091.	10.0	111
2	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35
3	Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. <i>Oncimmunology</i> , 2021, 10, 1909296.	4.6	13
4	Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. <i>BMC Medicine</i> , 2022, 20, 120.	5.5	5
5	De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 666145.	2.8	2
6	Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 4541-4551.	1.9	2
7	Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions. <i>Frontiers in Oncology</i> , 2021, 11, 772604.	2.8	1
8	Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. <i>BMC Medicine</i> , 2021, 19, 322.	5.5	0